The therapeutic use of stem cells for myelin repair in autoimmune demyelinating disorders

Stefano Pluchino, Gianvito Martino

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

Spontaneous remyelination occurs in multiple sclerosis (MS) patients. However, this process is not robust enough to promote a functional and stable recovery of the myelin architecture in demyelinated areas of the central nervous system (CNS). As a consequence of this incomplete reparative process, the disease invariably progresses and patchy areas of demyelination-in which axonal damage and/or loss is a constant accompanying factor-increase over time and lead to the accumulation of irreversible neurological deficits. Thus, the development of cell-based therapies aimed to promote multifocal remyelination in MS represents one of the most challenging areas of investigation. Several cell-replacement strategies have been developed in the last few years. However, most of these therapeutic approaches-although consistently able to form new myelin sheaths around the transplantation site-are unrealistic owing to the mutifocality of the demyelinating process and the inability to in vitro growth and differentiate large number of myelin-forming cells. Recently, promising cell-replacement therapies based on the use of stem cells have been proposed. However, before envisaging any potential human applications of such therapies we need to confront with some preliminary and still unsolved questions: (i) the ideal stem cell source for transplantation, (ii) the route of cell administration, (iii) the differentiation and persistence of stem cells into the targeted tissue and, last but not least, (iv) the functional and long-lasting integration of transplanted cells into the host tissue.

Original languageEnglish
Pages (from-to)117-119
Number of pages3
JournalJournal of the Neurological Sciences
Volume233
Issue number1-2
DOIs
Publication statusPublished - Jun 15 2005

Fingerprint

Demyelinating Diseases
Therapeutic Uses
Myelin Sheath
Stem Cells
Cell- and Tissue-Based Therapy
Multiple Sclerosis
Stem Cell Transplantation
Central Nervous System
Transplantation
Therapeutics
Growth

Keywords

  • Bone marrow
  • Cell-therapy
  • Demyelination
  • Multiple sclerosis
  • Neural stem cell
  • Neuroprotection
  • Remyelination
  • Stem cell
  • Transplantation

ASJC Scopus subject areas

  • Ageing
  • Clinical Neurology
  • Surgery
  • Neuroscience(all)
  • Developmental Neuroscience
  • Neurology

Cite this

The therapeutic use of stem cells for myelin repair in autoimmune demyelinating disorders. / Pluchino, Stefano; Martino, Gianvito.

In: Journal of the Neurological Sciences, Vol. 233, No. 1-2, 15.06.2005, p. 117-119.

Research output: Contribution to journalArticle

@article{6699bf76dbee46a188957c2e1c30d780,
title = "The therapeutic use of stem cells for myelin repair in autoimmune demyelinating disorders",
abstract = "Spontaneous remyelination occurs in multiple sclerosis (MS) patients. However, this process is not robust enough to promote a functional and stable recovery of the myelin architecture in demyelinated areas of the central nervous system (CNS). As a consequence of this incomplete reparative process, the disease invariably progresses and patchy areas of demyelination-in which axonal damage and/or loss is a constant accompanying factor-increase over time and lead to the accumulation of irreversible neurological deficits. Thus, the development of cell-based therapies aimed to promote multifocal remyelination in MS represents one of the most challenging areas of investigation. Several cell-replacement strategies have been developed in the last few years. However, most of these therapeutic approaches-although consistently able to form new myelin sheaths around the transplantation site-are unrealistic owing to the mutifocality of the demyelinating process and the inability to in vitro growth and differentiate large number of myelin-forming cells. Recently, promising cell-replacement therapies based on the use of stem cells have been proposed. However, before envisaging any potential human applications of such therapies we need to confront with some preliminary and still unsolved questions: (i) the ideal stem cell source for transplantation, (ii) the route of cell administration, (iii) the differentiation and persistence of stem cells into the targeted tissue and, last but not least, (iv) the functional and long-lasting integration of transplanted cells into the host tissue.",
keywords = "Bone marrow, Cell-therapy, Demyelination, Multiple sclerosis, Neural stem cell, Neuroprotection, Remyelination, Stem cell, Transplantation",
author = "Stefano Pluchino and Gianvito Martino",
year = "2005",
month = "6",
day = "15",
doi = "10.1016/j.jns.2005.03.026",
language = "English",
volume = "233",
pages = "117--119",
journal = "Journal of the Neurological Sciences",
issn = "0022-510X",
publisher = "Elsevier",
number = "1-2",

}

TY - JOUR

T1 - The therapeutic use of stem cells for myelin repair in autoimmune demyelinating disorders

AU - Pluchino, Stefano

AU - Martino, Gianvito

PY - 2005/6/15

Y1 - 2005/6/15

N2 - Spontaneous remyelination occurs in multiple sclerosis (MS) patients. However, this process is not robust enough to promote a functional and stable recovery of the myelin architecture in demyelinated areas of the central nervous system (CNS). As a consequence of this incomplete reparative process, the disease invariably progresses and patchy areas of demyelination-in which axonal damage and/or loss is a constant accompanying factor-increase over time and lead to the accumulation of irreversible neurological deficits. Thus, the development of cell-based therapies aimed to promote multifocal remyelination in MS represents one of the most challenging areas of investigation. Several cell-replacement strategies have been developed in the last few years. However, most of these therapeutic approaches-although consistently able to form new myelin sheaths around the transplantation site-are unrealistic owing to the mutifocality of the demyelinating process and the inability to in vitro growth and differentiate large number of myelin-forming cells. Recently, promising cell-replacement therapies based on the use of stem cells have been proposed. However, before envisaging any potential human applications of such therapies we need to confront with some preliminary and still unsolved questions: (i) the ideal stem cell source for transplantation, (ii) the route of cell administration, (iii) the differentiation and persistence of stem cells into the targeted tissue and, last but not least, (iv) the functional and long-lasting integration of transplanted cells into the host tissue.

AB - Spontaneous remyelination occurs in multiple sclerosis (MS) patients. However, this process is not robust enough to promote a functional and stable recovery of the myelin architecture in demyelinated areas of the central nervous system (CNS). As a consequence of this incomplete reparative process, the disease invariably progresses and patchy areas of demyelination-in which axonal damage and/or loss is a constant accompanying factor-increase over time and lead to the accumulation of irreversible neurological deficits. Thus, the development of cell-based therapies aimed to promote multifocal remyelination in MS represents one of the most challenging areas of investigation. Several cell-replacement strategies have been developed in the last few years. However, most of these therapeutic approaches-although consistently able to form new myelin sheaths around the transplantation site-are unrealistic owing to the mutifocality of the demyelinating process and the inability to in vitro growth and differentiate large number of myelin-forming cells. Recently, promising cell-replacement therapies based on the use of stem cells have been proposed. However, before envisaging any potential human applications of such therapies we need to confront with some preliminary and still unsolved questions: (i) the ideal stem cell source for transplantation, (ii) the route of cell administration, (iii) the differentiation and persistence of stem cells into the targeted tissue and, last but not least, (iv) the functional and long-lasting integration of transplanted cells into the host tissue.

KW - Bone marrow

KW - Cell-therapy

KW - Demyelination

KW - Multiple sclerosis

KW - Neural stem cell

KW - Neuroprotection

KW - Remyelination

KW - Stem cell

KW - Transplantation

UR - http://www.scopus.com/inward/record.url?scp=20444423819&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20444423819&partnerID=8YFLogxK

U2 - 10.1016/j.jns.2005.03.026

DO - 10.1016/j.jns.2005.03.026

M3 - Article

VL - 233

SP - 117

EP - 119

JO - Journal of the Neurological Sciences

JF - Journal of the Neurological Sciences

SN - 0022-510X

IS - 1-2

ER -